Merck & Company Inc (MRK)vsVericel Corp Ord (VCEL)
MRK
Merck & Company Inc
$110.95
-1.60%
HEALTHCARE · Cap: $274.03B
VCEL
Vericel Corp Ord
$33.43
-6.23%
HEALTHCARE · Cap: $1.82B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 23433% more annual revenue ($65.01B vs $276.26M). MRK leads profitability with a 28.1% profit margin vs 6.0%. MRK trades at a lower P/E of 15.2x. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
VCEL
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$110.95
$14.47 premium
Margin of Safety
-48.8%
Fair Value
$23.27
Current Price
$33.43
$10.16 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Strong operational efficiency at 24.1%
Revenue surging 23.3% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Smaller company, higher risk/reward
ROE of 5.1% — below average capital efficiency
6.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : VCEL
The strongest argument for VCEL centers on Operating Margin, Revenue Growth. Revenue growth of 23.3% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : VCEL
The primary concerns for VCEL are Market Cap, Return on Equity, Profit Margin. A P/E of 111.4x leaves little room for execution misses.
Key Dynamics to Monitor
MRK profiles as a value stock while VCEL is a growth play — different risk/reward profiles.
VCEL carries more volatility with a beta of 1.21 — expect wider price swings.
VCEL is growing revenue faster at 23.3% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 48/100), backed by strong 28.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Vericel Corp Ord
HEALTHCARE · BIOTECHNOLOGY · USA
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cell therapies for the sports medicine and severe burn care markets in the United States. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?